Crinetics Pharmaceuticals, Inc. (CRNX) — Financial statements
Income statement, balance sheet, and cash flow for Crinetics Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 8↑640.7% | 1↓74.1% | 4↓15.3% | 5↑339.4% | 1 | |
| Cost of Revenue | 1 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 7↑537.2% | 1↓74.1% | 4↓15.3% | 5↑339.4% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 332↑38.3% | 240↑42.5% | 169↑29.4% | 130↑54.6% | 84 | |
| General & Administrative Expenses | 191↑91.8% | 100↑71.7% | 58↑37.0% | 42↑72.9% | 25 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 191↑91.8% | 100↑71.7% | 58↑37.0% | 42↑72.9% | 25 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 523↑54.0% | 340↑50.0% | 227↑31.3% | 173↑58.7% | 109 | |
| Total Costs & Expenses | 524↑54.3% | 340↑50.0% | 227↑31.3% | 173↑58.7% | 109 | |
| Operating Results | ||||||
| Operating Income | -517↓52.5% | -339↓52.2% | -223↓32.6% | -168↓55.9% | -108 | |
| Depreciation & Amortization | 4↑39.7% | 3↑153.6% | 1↑11.7% | 0.98↑6.6% | 0.92 | |
| EBITDA | -513↓52.6% | -336↓51.7% | -222↓32.7% | -167↓56.3% | -107 | |
| EBIT | -517↓52.5% | -339↓52.2% | -223↓32.6% | -168↓55.9% | -108 | |
| Interest & Other Income | ||||||
| Net Interest Income | 52↑25.5% | 41↑208.4% | 13↑211.2% | 4↑2649.7% | 0.16 | |
| Interest Income | 52↑25.5% | 41↑208.4% | 13↑211.2% | 4↑2649.7% | 0.16 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 52↑27.7% | 40↑400.6% | 8↑103.8% | 4↑6398.4% | 0.06 | |
| Income Before Tax | -465↓55.9% | -298↓39.1% | -215↓30.9% | -164↓52.3% | -108 | |
| Income Tax Expense | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -465↓55.9% | -298↓39.1% | -215↓30.9% | -164↓52.3% | -108 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -465↓55.9% | -298↓39.1% | -215↓30.9% | -164↓52.3% | -108 | |
| Bottom-Line Net Income | -465↓55.9% | -298↓39.1% | -215↓30.9% | -164↓52.3% | -108 | |
| EPS (Basic) | -4.95↓34.1% | -3.69↑0.0% | -3.69↓17.1% | -3.15↓12.5% | -2.80 | |
| EPS (Diluted) | -4.95↓34.1% | -3.69↑0.0% | -3.69↓17.1% | -3.15↓12.5% | -2.80 | |
| Weighted Average Shares | 94↑16.4% | 81↑39.1% | 58↑11.7% | 52↑35.2% | 38 | |
| Weighted Average Diluted Shares | 94↑16.4% | 81↑39.1% | 58↑11.7% | 52↑35.2% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.